ADIPOQ and hepatocellular carcinoma: Interestingly, we observed that circulating biomarkers such as PIVKA-II and adiponectin displayed a good performance for the discrimination between patients with HCC and those without tumors; remarkably, the combination of demographic features (i.e., age and gender) together with oncogenic markers (i.e., PIVKA-II and GPC-3) and markers of adipose tissue dysfunction (i.e., adiponectin) allowed the development of a model showing an excellent performance for the detection of HCC.